Tamara van Donge

Chapter 3 56 39. Zaidi AK, Tikmani SS, Warraich HJ, et al. Community-based treatment of serious bacterial infections in newborns and young infants: a randomized controlled trial assessing three antibiotic regimens. The Pediatric infectious disease journal. 2012;31(7):667-672. 40. Toutain P-L, Bousquet-Mélou A, Martinez M. AUC/MIC: a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor? Journal of Antimicrobial Chemotherapy. 2007;60(6):1185-1188. 41. Kishk OA, Lardieri AB, Heil EL, Morgan JA. Vancomycin AUC/MIC and corresponding troughs in a pediatric population. The Journal of Pediatric Pharmacology and Therapeutics. 2017;22(1):41-47. 42. Zea-Vera A, Ochoa TJ. Challenges in the diagnosis and management of neonatal sepsis. Journal of tropical pediatrics. 2015;61(1):1-13. 43. Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. MIC-based dose adjustment: facts and fables. Journal of Antimicrobial Chemotherapy. 2017. 44. van den Anker JN, Knibbe CA, Tibboel D. Augmented Renal Clearance in Critically Ill Pediatric Patients: Does It Impact the Outcome of Pharmacotherapy? Pediatric Critical Care Medicine. 2017;18(9):901-902. 45. Standing JF. Understanding and applying pharmacometric modelling and simulation in clinical practice and research. British Journal of Clinical Pharmacology. 2017;83(2):247-254. 46. Germovsek E, Kent A, Metsvaht T, et al. Development and evaluation of a gentamicin pharmacokinetic model that facilitates opportunistic gentamicin therapeutic drug monitoring in neonates and infants. Antimicrobial agents and chemotherapy. 2016;60(8):4869-4877. 47. Edginton AN, Schmitt W, Willmann S. Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children. Clinical Pharmacokinetics. 2006;45(10):1013-1034. 48. Nekka F, Csajka C, Wilbaux M, Sanduja S, Li J, Pfister M. Pharmacometrics-based decision tools facilitate mHealth implementation. Expert Review of Clinical Pharmacology. 2017;10(1):39-46. 49. Poggi C, Bianconi T, Gozzini E, Generoso M, Dani C. Presepsin for the detection of late-onset sepsis in preterm newborns. Pediatrics. 2015;135(1):68-75. 50. Montaldo P, Rosso R, Santantonio A, Chello G, Giliberti P. Presepsin for the detection of early-onset sepsis in preterm newborns. Pediatric research. 2017;81(2):329. 51. Bellos I, Fitrou G, Pergialiotis V, Thomakos N, Perrea DN, Daskalakis G. The diagnostic accuracy of presepsin in neonatal sepsis: a meta-analysis. European journal of pediatrics. 2018:1-8. 52. Müller M, dela Peña A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti- infective agents: distribution in tissue. Antimicrobial agents and chemotherapy. 2004;48(5):1441- 1453. 53. Liu P, Müller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. International journal of antimicrobial agents. 2002;19(4):285-290. 54. Barbour AM, Schmidt S, Zhuang L, Rand K, Derendorf H. Application of pharmacokinetic/ pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time–kill curve based approaches. International journal of antimicrobial agents. 2014;43(1):60-67. 55. De Cock PA, Standing JF, Barker CI, et al. Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children. Antimicrobial agents and chemotherapy. 2015;59(11):7027-7035. 56. Samardzic J, Allegaert K, Wilbaux M, Pfister M, van den Anker JN. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period. Expert opinion on drug metabolism & toxicology. 2016;12(4):367-375.